Navigation Links
Cara Therapeutics Initiates Phase 1 Clinical Trial of Novel Analgesic, CR845
Date:4/28/2008

SHELTON, Conn., April 28 /PRNewswire/ -- Cara Therapeutics, Inc. today announced that it has initiated a Phase 1 clinical trial of its long-acting peripheral kappa opioid receptor agonist, CR845. The Phase 1a single-center clinical trial will evaluate the safety, tolerability, pharmacokinetic profile, and pharmacological activity of CR845 in a double-blind, randomized, placebo-controlled, single escalating intravenous dose study in 58 healthy male and female volunteers.

The company is also developing oral and subcutaneous formulations of CR845.

About CR845

In preclinical studies, CR845 was highly selective for the peripheral kappa opioid receptor. Animal studies indicate that CR845 is effective in treating pain of inflammatory, neuropathic and visceral origin and exhibits analgesic efficacy for up to 18 hours after a single dose. Analgesic activity was seen after intravenous, subcutaneous, or oral administration. Unlike currently marketed opioids, CR845 did not inhibit intestinal transit (ileus) or elicit signs of addiction in animal models. Preclinical studies also indicate that CR845 possesses anti-itch activity.

About Cara Therapeutics

Cara Therapeutics is a privately held biotechnology company focused on developing novel, superior therapeutics to treat pain and inflammation associated with diverse medical conditions. Cara's current pipeline includes near-term clinical drug candidates identified as mechanistically distinct, peripherally-acting analgesics.

Forward-Looking Statements

Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements relating to the therapeutic applications of CR845 and about Cara's strategy, technologies, pre-clinical and clinical programs, and ability to identify and develop drugs, as well as other statements that are not historical facts. Actual events or results may dif
'/>"/>

SOURCE Cara Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. PTC Therapeutics Announces Initiation of Phase 2b Registration-Directed Clinical Trial of PTC124 in Duchenne/Becker Muscular Dystrophy
2. Halozyme Therapeutics Presents Findings on Combinations of rHuPH20 Enzyme With Bisphosphonates at the American Association for Cancer Research Conference
3. Halozyme Therapeutics Presents Pre-Clinical Studies of Systemic Delivery of Pegylated rHuPH20 Enyzme in Prostate Cancer Models at American Association for Cancer Research Conference
4. Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings
5. Echo Therapeutics Announces Positive Results with the Prelude(TM) SkinPrep System, the Next-Generation Skin Permeation Medium for its Symphony(TM) Transdermal Continuous Glucose Monitoring System
6. Recent siRNA Research Publications Support Silence Therapeutics Combined Development Approach
7. European Regulatory Agency Accepts Cell Therapeutics, Inc.s Marketing Authorization Application for XYOTAX(TM) for Lung Cancer for Review
8. CV Therapeutics Anti-Ischemic Therapy Ranexa(R) Significantly Reduces Cardiac Chest Pain Symptoms and Recurrent Ischemia in MERLIN-TIMI 36 Patients With Angina
9. Michael J. Fox Foundation Commits up to $10 Million for Pre-Clinical Drug Development Under Therapeutics Development Initiative
10. Synvista Therapeutics Presents New Preclinical Data Demonstrating the Value of Haptoglobin Genotype Testing In Diabetes at ACC Scientific Sessions
11. Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... , March 5, 2015 BioLineRx (NASDAQ: ... biopharmaceutical company dedicated to identifying, in-licensing and developing ... commenced an underwritten public offering of American Depositary ... Ordinary Shares. All of the ADSs in the ... JMP Securities is acting as sole ...
(Date:3/5/2015)... 5. März 2015  Die amerikanische Bill ... biopharmazeutische Unternehmen CureVac geben heute bekannt, dass ... US-Dollar) in CureVac investiert. CureVac ist weltweit ... (mRNA). Auf Basis dieses Moleküls entwickelt CureVac ... und zum Schutz vor Infektionskrankheiten. ...
(Date:3/5/2015)... -- CANTEL MEDICAL CORP. (NYSE: CMN ) will ... 2015 on Thursday, March 12 before the market opens, and ... AM ET. To participate in the conference ... the beginning of the call. If you are unable to ... from Thursday, March 12, 2015 through midnight on May 12, ...
Breaking Medicine Technology:BioLineRx Announces Underwritten Public Offering of its American Depositary Shares 2BioLineRx Announces Underwritten Public Offering of its American Depositary Shares 3Bill & Melinda Gates Stiftung investiert in CureVac zur Entwicklung innovativer Impfstoffe 2Bill & Melinda Gates Stiftung investiert in CureVac zur Entwicklung innovativer Impfstoffe 3Bill & Melinda Gates Stiftung investiert in CureVac zur Entwicklung innovativer Impfstoffe 4Cantel Medical Corp. To Hold Conference Call To Discuss Results For Its Second Quarter Ended January 31, 2015 2
...  BioMed Realty Trust, Inc. (NYSE: BMR ) ... with Depomed, Inc. (NASDAQ: DEPO ) at ... a specialty pharmaceutical company, leased approximately 60,000 square feet ... Realty,s multi-tenant Pacific Research Center campus. Commenting ...
... Fla., April 9, 2012 Med-Tek a developer of Healthcare ... physicians, employers and their constituents today announces the launch ... According to the United States Bone ... individuals suffering from musculoskeletal disease ...
Cached Medicine Technology:New 60,000 Square Foot Lease at the Pacific Research Center Signed by Biomed Realty and Depomed 2New 60,000 Square Foot Lease at the Pacific Research Center Signed by Biomed Realty and Depomed 3Med-Tek Launches the First Evidenced Based Opioid Management Program (OMP) 2
(Date:3/5/2015)... Central Nebraska Imaging (CNI) is pleased ... brand’s new logo and optimized website. , ... approach to expert diagnostic imaging, centered on patient care. ... to be a resource for Nebraska patients and a ... communication and referral functionality, video content and resources to ...
(Date:3/5/2015)... 05, 2015 HomeCEUConnection.com is ... with extra savings on their nutrition CEUs. ... health and nutrition, HomeCEUConnection.com is offering 10% ... promo code, NUTRITION2015 . , High ... , HomeCEUConnection.com provides high-quality continuing education courses ...
(Date:3/5/2015)... CA (PRWEB) March 05, 2015 On ... titled “Butt Augmentation, Labiaplasty on the Rise, Plastic Surgeons ... by the American Society for Aesthetic Plastic Surgery ... . Both groups reported a year-over-year doubling of surgical ... the physicians quoted in the article, this increase can ...
(Date:3/5/2015)... (PRWEB) March 05, 2015 In honor ... to shatter myths about drug and alcohol abuse in ... released a Fact Sheet with information on some of ... in 2010 by the National Institute on Drug Abuse, ... alcohol aims to counteract the illusions that teens and ...
(Date:3/5/2015)... At the 7th Annual Mississippi Addiction ... treatment met today in Jackson, Mississippi to listen to ... the numerous respected speakers will be William S. ... that pain medications have had in today’s opiate overdose ... "It is hard to believe that much of the ...
Breaking Medicine News(10 mins):Health News:Central Nebraska Imaging Center Gets Rebranding 2Health News:HomeCEUConnection.com Offers Nutrition CEUs this March to Celebrate Nutrition Month 2Health News:The Kim Kardashian and Jennifer Lopez Effect: Butt Augmentations Double from 2013 to 2014 2Health News:A Forever Recovery Issues New Tips for Sobriety for National Drug Facts Week 2Health News:National Addiction Treatment Expert William S. “Bill” Jacobs, Md Speaks At Prestigious 7th Annual Mississippi Addiction Conference 2Health News:National Addiction Treatment Expert William S. “Bill” Jacobs, Md Speaks At Prestigious 7th Annual Mississippi Addiction Conference 3
... Rights to Bystolic(TM) (Nebivolol) for $370 Million in Cash ... To Consider a Sale of Dey Specialty Business, PITTSBURGH, Feb. ... results for the three and nine months ended,December 31, 2007, provided ... announced a number of strategic and operational,initiatives., Financial Highlights, ...
... New research from a scientist at the University of ... to a better flu vaccine. , While the research ... findings from Mark Sangster, a professor of microbiology, track ... infection and reveal new information about where it is ...
... University School of Medicine and Harvard Medical School have ... of high blood pressure, reduces cocaine cravings in a ... issue of the leading medical journal Nature Neuroscience. , ... glutamate, independently contribute to the development of cocaine addiction. ...
... ROCKVILLE, Md., Feb. 27 Novavax, Inc.,(Nasdaq: NVAX ... Singhvi, President and Chief Executive Officer, will be presenting ... 12:30 p.m. on March 4, 2008 at The W ... of the company,s strategy, research and,development progress. A link ...
... 27 Dr. Shawn Hook of Arbor Ridge,Clinic in ... Summit,VetPharm,s "The Great Vectra 3D(TM)" $125,000 Giveaway. Dr. Hook ... receive $25,000 in,medical equipment for his veterinary clinic. There ... February and March, and a final grand prize,winner who ...
... numbers of circulating,cancer cells in a blood sample; ... RARITAN, N.J., Feb. 27 Veridex, LLC ... (FDA) has granted an expanded,clearance for the CellSearch(TM) ... the,monitoring of metastatic prostate cancer (MPC) patients. The ...
Cached Medicine News:Health News:Mylan Reports Adjusted Diluted Cash EPS of $0.11 for the Quarter 2Health News:Mylan Reports Adjusted Diluted Cash EPS of $0.11 for the Quarter 3Health News:Mylan Reports Adjusted Diluted Cash EPS of $0.11 for the Quarter 4Health News:Mylan Reports Adjusted Diluted Cash EPS of $0.11 for the Quarter 5Health News:Mylan Reports Adjusted Diluted Cash EPS of $0.11 for the Quarter 6Health News:Mylan Reports Adjusted Diluted Cash EPS of $0.11 for the Quarter 7Health News:Mylan Reports Adjusted Diluted Cash EPS of $0.11 for the Quarter 8Health News:Mylan Reports Adjusted Diluted Cash EPS of $0.11 for the Quarter 9Health News:Mylan Reports Adjusted Diluted Cash EPS of $0.11 for the Quarter 10Health News:Mylan Reports Adjusted Diluted Cash EPS of $0.11 for the Quarter 11Health News:Mylan Reports Adjusted Diluted Cash EPS of $0.11 for the Quarter 12Health News:Mylan Reports Adjusted Diluted Cash EPS of $0.11 for the Quarter 13Health News:Mylan Reports Adjusted Diluted Cash EPS of $0.11 for the Quarter 14Health News:Mylan Reports Adjusted Diluted Cash EPS of $0.11 for the Quarter 15Health News:UT Knoxville research may lead to better flu vaccine 2Health News:Summit VetPharm Announces First Winner in its 'Great Vectra 3D(TM)' $125,000 Giveaway 2Health News:FDA Clears Cellsearch(TM) Circulating Tumor Cell Test for Monitoring Metastatic Prostate Cancer Patients 2Health News:FDA Clears Cellsearch(TM) Circulating Tumor Cell Test for Monitoring Metastatic Prostate Cancer Patients 3Health News:FDA Clears Cellsearch(TM) Circulating Tumor Cell Test for Monitoring Metastatic Prostate Cancer Patients 4
Colloidal Gold Conjugated, Goat anti-human IgA (Alpha Chain) - 50 OD...
Polyester ribbon impregnated with conjugated Protein A - .50 OD per sq. cm....
Polyester ribbons (3) impregnated with different OD values of conjugated Protein G...
Colloidal Gold Sol, 80 nm - 12 - 15 OD, 1 ml, Gold Sol Nanoparticles - not boiled, not centrifuged...
Medicine Products: